Showing 176–200 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Bada FO, Blok N, Okpokoro E, Dutt S, Akolo C, et al.
…d treatment success rates of 52-66% while shorter treatment regimens have reported success rates of 85% and above. In addition, replacing the second-line injectable agent in a shorter treatment regimen with bedaquiline has been found to further improve treatment success in patien…
Weng T, Sun F, Li Y, Chen J, Chen X, et al.
… to treat, pressing more effective and innovative treatment regimens. New efficient regimens for MDR-TB have obtained high treatment success rates. However, those regimens without drug susceptibility testing (DST) are also likely to contribute to the emergence of resistance. Prec…
Morgan H, Ndjeka N, Hasan T, Gegia M, Mirzayev F, et al.
…n. We evaluated treatment outcomes for patients assigned to regimens including linezolid in 2019 and ethionamide in 2017. Methods This retrospective cohort study included patients treated for multidrug-resistant/rifampicin-resistant tuberculosis throughout South Africa between 1 …
Trébucq A, Decroo T, Van Deun A, Piubello A, Chiang CY, et al.
…ug-resistant tuberculosis (MDR-TB) treatment. Similar short regimens were studied in different settings, relying for their efficacy on a later generation fluoroquinolone, either gatifloxacin, moxifloxacin, or levofloxacin. We review the published material on short MDR-TB regimens…
Kou Y, Wan M, Shi W, Liu J, Zhao Z, et al.
…of the homologous and heterologous prime-boost immunization regimens of these two viral vector-based vaccines remains unclear. In the present study, we constructed recombinant Ad and MVA expressing an Ag85B-TB10.4 fusion protein (AdH4 and MVAH4) and evaluated the impact of their …
Edmund Shen, Mikanda Kwabisha Kunda, Stephane Mpinda, Allison LaHood, Letizia Trevisi, et al.
…. Historically, effective therapy was hindered by prolonged regimens and drug toxicity. Recent clinical trials and observational studies demonstrated the potential of shortened all-oral regimens in improving treatment outcomes, leading the WHO to recommend several standardized 6 …
Rathinam Sridhar
…ntroducing short-course 9–12 months all oral Bdq containing regimens with specific inclusion and exclusion criteria.[1] All oral Bdq-based shorter regimens significantly improved sputum culture conversions and treatment success while reducing mortality and treatment failures.[2] …
Kendra Brett, Melissa Severn
…r treating active tuberculosis (TB), some 4-month treatment regimens may be as effective and safe as the standard 6-month treatment regimen. However, there are also 4-month treatment regimens that seem to be less effective than the 6-month treatment regimen for treating active TB…
Christoph Lange, Yousra Kherabi, Lorenzo Guglielmetti, Raquel Duarte, Gunar Günther
In the recent manuscript by Günther G. et al. “Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe”, published in this journal ( 1 Günther G, Guglielmetti L, Kherabi Y, Duarte R, Lange C; Tuberculosis Network European Tri…
Tmp Nguyen, T.H.M. Le, C.S.C. Merle, L. Guglielmetti, N.L. Nguyen, et al.
… in the same year. 1 In 2025, the WHO recommended different regimens for RR-TB patients without confirmed fluoroquinolones (FQ) resistance, one of which is a 5-drug 9-month treatment regimen, based on results of the endTB clinical trial.This so called BCLLfxZ regimen includes bed…
Pankaj Jorwal, Anivita Aggarwal, Parul Kodan, Nitin Gupta, Sudeshna Ghosh, et al.
…e difficulty in its diagnosis, the long course of treatment regimens is associated with multiple side-effects, poor compliance and undesirable rate of a positive outcome. Before the availability of newer treatment regimens and newer drugs, positive outcomes in patients with XDR-T…
Mutong Fang, Sinian Li, Xiangxiang Liu, Guoju Shao, Zhi Mao, et al.
…ety between bedaquiline(Bdq) and non-bedaquiline containing regimens for treatment of Pre XDR-TB. Meanwhile, we analyze the outcomes among different Bdq duration and total regimen duration. P < 0.05 is significantly different, GraphPad prism 5.0 software package was used to pr…
P Muneera, Grinish Tamakuwala, Jignesh Gengadiya, Parul Vadgama
…inal outcome, and ADRs in RR-TB patients taking shorter MDR regimens. Materials and Methods: Prospective observational longitudinal study which was carried out in the Department of Respiratory Medicine Department, New Civil Hospital, Surat from January 2019 to June 2020. All pati…
Mireille Avilaw Mpwate, Eddy Mampuya Mbambu, Christian Nzanza Matanda, Gabriel Mabwaka Lema, Michel Kaswa, et al.
…me between the two groups of patients on AG and bedaquiline regimens. The double-difference method was estimated using regression with fixed-effects. A p value Results: The degree of hearing loss was similar between the two groups at the first month [AGs (28 dB) vs BDQ (30 dB); p…
Rahul Verma
…ifficult and challenging treatment. There are two treatment regimens for MDR-TB treatment. Objectives: To compare the predisposing risk factors and treatment outcomes in two different drug regimens for the treatment of MDR-TB. Material and methods: A field based longitudinal stud…
Vincent M. Balanag, Vivian Lofranco, Mariquita J. Mantala, Mary Rosary T. Santiago, Patrice Jamie E. Cabasis, et al.
… have shown the potential benefits of adding bedaquiline to regimens for drug-resistant TB (DR-TB). In search of more effective regimens for DR-TB, bedaquiline was introduced in the TB program in the Philippines under operational research to assess its effectiveness, safety, and …
H. Mursaloglu, Can Akın, Cansu Yilmaz, Pınar Ergenekon, Yasemi̇n Gökdemi̇r, et al.
…redictors of treatment failure, the efficacy of eradication regimens and long-term clinical outcome in our CF center. <b>Methods:</b> 309 patients were involved in the study. All sputum cultures collected between 2015-2019 were reviewed. Clinical findings, demographics and eradic…
Natalia Yatskevich, G. L. Gurevich, E. M. Skryagina, Elmira Gurbanova
… to evaluate the effectiveness of 39- and 24-week treatment regimens in patients with multiple drug resistant or rifampicin-resistant tuberculosis (MDR/RR-TB). Subjects and Methods . We evaluated the effectiveness of 39- and 24-week treatment regimens containing bedaquiline, levo…
Muhamad Frendy Setyawan, Ni Made Mertaniasih, Soedarsono Soedarsono
BACKGROUND: The use of bedaquiline has been reported to minimize the number of lost to follow-up and fewer rejections from the patients. This study is the first to depict the use of bedaquiline. It aims to provide information related to the profile of the MDR-TB drug regimen in t…
Lee BY, Clemens DL, Silva A, Dillon BJ, Masleša-Galić S, et al.
…ic response surface (PRS) platform, we have identified drug regimens that treat tuberculosis more rapidly in mice than the current Standard Regimen used in humans. We show that PRS Regimen III, comprising clofazimine, SQ109, bedaquiline and pyrazinamide, rapidly sterilizes the lu…
James LP, Klaassen F, Sweeney S, Furin J, Franke MF, et al.
…ging evidence suggests that shortened, simplified treatment regimens for rifampicin-resistant tuberculosis (RR-TB) can achieve comparable end-of-treatment (EOT) outcomes to longer regimens. We compared a 6-month regimen containing bedaquiline, pretomanid, linezolid, and moxifloxa…
Evans D, Hirasen K, Ramushu C, Long L, Sinanovic E, et al.
… medical patient costs were negligible across all treatment regimens, while direct non-medical patient and guardian costs for travel, food and nutritional supplementation accounted for the largest proportion of total costs ($54.6, $227.8 and $224.3 for BPaL, the SSOR and SLOR res…
Strydom N, van Wijk RC, Wang Q, Ernest JP, Chaba L, et al.
…g discovery has increased the number of plausible multidrug regimens. Testing every drug combination in vivo is impractical, and varied experimental conditions make it challenging to compare results between experiments. Using published treatment efficacy data from a mouse tubercu…
Soeroto AY, Nurhayati RD, Purwiga A, Lestari BW, Pratiwi C, et al.
Background and aims Multi drug or rifampicin resistant tuberculosis (MDR/RR-TB) is a major burden to TB prevention and eradication globally. Since 2016, WHO guidelines have included options for treating MDR/RR-TB with a standard regimen of 9 to 11 months duration (the 'shorter re…
Shaojun Zhang, Yang Yan, Wenwen Sun, Zhong-Shun Zhang, Heping Xiao, et al.
…s and safety of bedaquiline-containing and bedaquiline-free regimens for treatment of patients with refractory rifampicin-resistant/multidrug-resistant tuberculosis (RR/MDR-TB). Methods: Patients with refractory RR/MDR-TB receiving bedaquiline-containing regimens (bedaquiline gro…